ASP Isotopes Inc. (ASPI)
NasdaqCM · Chemicals
Scores are generated from technical indicators for educational purposes and are not a recommendation to buy or sell.
Price history
Daily closes and volumeAI Analysis Generated from the indicator readings below. Educational only.
ASP Isotopes Inc. is trading at $3.94, down 1.99% on the session. The 50 day average sits at $5.22 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 45.6, which reads as neutral, and MACD is bullish crossover. Volume is below average.
The nearest support is around $3.61 with resistance near $4.40, so that band frames the current range. Average daily movement is roughly $0.32, or about 8.2% of the share price, which is what any stop placement has to allow for. The overall health score of 40 out of 100 combines a trend score of 25, momentum of 73 and a risk score of 18.
Technical indicators
About ASP Isotopes Inc.
ASP Isotopes Inc., a development stage advanced materials company, engages in the production, distribution, marketing, and sale of isotopes in South Africa,Hong Kong, and United States. It operates in two segments, Nuclear Fuels, and Specialist Isotopes and Related Services. The Nuclear Fuels segment focuses on the research and development of technologies and methods used to produce high-assay low-enriched uranium (HALEU) and Lithium-6 for the advanced nuclear fuels target end market. Its Specialist Isotopes and Related Services segment engages in the research and development of technologies and methods used to separate high-value, low-volume isotopes, such as C-14, Mo-100 and Si-28, for target end markets, including pharmaceuticals and agrochemicals, nuclear medical imaging, and semiconductors; provision of related services; and operation of PET labs. The company offers the Aerodynamic Separation Process (ASP) technology, which separates gas species and isotopes in a volatile state; and the Quantum Enrichment (QE) technology, which separates isotopes. It also produces and commercializes Molybdenum-100, Molybdenum-98, and Ytterbium-176 for the nuclear medical industry. In addition, the company develops Zinc-68, Nickel-64, and Xenon-129/136 for the nuclear medical industry; Lithium-7, Uranium-235, and Chlorine-37 for the energy industry; and Germanium-70/72/74 for semiconductor markets. The company was incorporated in 2021 and is based in Dallas, Texas.
Company website